Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.6% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 0.6% on Thursday . The company traded as high as $6.53 and last traded at $6.26. Approximately 6,932,748 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 6,639,027 shares. The stock had previously closed at $6.22.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Leerink Partners cut their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group lowered their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The firm has a market capitalization of $1.73 billion, a P/E ratio of -3.94 and a beta of 0.85. The company has a 50-day moving average price of $6.76 and a 200-day moving average price of $7.20.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.43) earnings per share. On average, sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $6.22, for a total value of $71,200.34. Following the completion of the transaction, the director now directly owns 7,098,428 shares of the company’s stock, valued at approximately $44,152,222.16. This represents a 0.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Tina Marriott sold 6,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The trade was a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 107,788 shares of company stock valued at $724,691 in the last quarter. Company insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its holdings in shares of Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after acquiring an additional 288,926 shares in the last quarter. FMR LLC increased its position in shares of Recursion Pharmaceuticals by 2.1% during the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. State Street Corp raised its stake in shares of Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at approximately $5,769,000. Finally, Pier 88 Investment Partners LLC grew its stake in shares of Recursion Pharmaceuticals by 442.1% in the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after buying an additional 109,210 shares in the last quarter. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.